SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Want to cut your energy bills? Here’s how five experts are doing it 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
CARMIEL, Israel, March 09, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2016 financial results and provide a corporate update on Thursday, March 16, 2017 at 8:30 am ET.
To participate in the conference call, please dial the following numbers prior to the start of the call: United States: +1-844-358-6760; International: +1-478-219-0004. The conference call will also be broadcast live and available for replay for two weeks on the Company's website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
